Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)
Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –
Vericel gross margin
Gross margin is gross profit as a percentage of revenue.
Vericel's gross margin for the twelve months ending Sep 30, 2026 was 74.5%. For fiscal 2025 it was 74.4%, against 72.6% the year before. The highest annual figure on record is 78.9% in fiscal 2013.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 74.4% | +1.9 |
| FY2024 | Dec 31, 2024 | 72.6% | +3.9 |
| FY2023 | Dec 31, 2023 | 68.6% | +1.8 |
| FY2022 | Dec 31, 2022 | 66.8% | −1.1 |
| FY2021 | Dec 31, 2021 | 67.9% | +0.1 |
| FY2020 | Dec 31, 2020 | 67.8% | −0.3 |
| FY2019 | Dec 31, 2019 | 68.1% | +3.5 |
| FY2018 | Dec 31, 2018 | 64.6% | +12.1 |
| FY2017 | Dec 31, 2017 | 52.5% | +4.6 |
| FY2016 | Dec 31, 2016 | 47.9% | −0.3 |
| FY2015 | Dec 31, 2015 | 48.3% | +8.3 |
| FY2014 | Dec 31, 2014 | 39.9% | −39.0 |
| FY2013 | Dec 31, 2013 | 78.9% | +7.5 |
| FY2012 | Dec 31, 2012 | 71.4% | +9.6 |
| FY2010 | Jun 30, 2010 | 61.8% | +23.3 |
| FY2009 | Jun 30, 2009 | 38.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 73.3% | −0.1 |
| Q2 FY2026 | Jun 30, 2026 | 72.8% | −0.9 |
| Q1 FY2026 | Mar 31, 2026 | 72.0% | +3.0 |
| Q4 FY2025 | Dec 31, 2025 | 78.7% | +1.1 |
| Q3 FY2025 | Sep 30, 2025 | 73.5% | +1.5 |
| Q2 FY2025 | Jun 30, 2025 | 73.7% | +4.2 |
| Q1 FY2025 | Mar 31, 2025 | 69.0% | +0.0 |
| Q4 FY2024 | Dec 31, 2024 | 77.6% | +3.0 |
| Q3 FY2024 | Sep 30, 2024 | 71.9% | +4.8 |
| Q2 FY2024 | Jun 30, 2024 | 69.5% | +4.3 |
| Q1 FY2024 | Mar 31, 2024 | 68.9% | +4.3 |
| Q4 FY2023 | Dec 31, 2023 | 74.6% | +2.0 |
| Q3 FY2023 | Sep 30, 2023 | 67.2% | +1.7 |
| Q2 FY2023 | Jun 30, 2023 | 65.2% | +3.5 |
| Q1 FY2023 | Mar 31, 2023 | 64.7% | −0.4 |
| Q4 FY2022 | Dec 31, 2022 | 72.6% | +1.1 |
| Q3 FY2022 | Sep 30, 2022 | 65.5% | +1.4 |
| Q2 FY2022 | Jun 30, 2022 | 61.7% | −6.4 |
| Q1 FY2022 | Mar 31, 2022 | 65.0% | −1.5 |
| Q4 FY2021 | Dec 31, 2021 | 71.5% | −2.9 |
| Q3 FY2021 | Sep 30, 2021 | 64.0% | −5.6 |
| Q2 FY2021 | Jun 30, 2021 | 68.1% | +11.4 |
| Q1 FY2021 | Mar 31, 2021 | 66.5% | +3.7 |
| Q4 FY2020 | Dec 31, 2020 | 74.4% | +1.3 |
| Q3 FY2020 | Sep 30, 2020 | 69.7% | +0.2 |
| Q2 FY2020 | Jun 30, 2020 | 56.7% | −8.8 |
| Q1 FY2020 | Mar 31, 2020 | 62.8% | +2.4 |
| Q4 FY2019 | Dec 31, 2019 | 73.1% | +0.7 |
| Q3 FY2019 | Sep 30, 2019 | 69.4% | +5.6 |
| Q2 FY2019 | Jun 30, 2019 | 65.5% | +6.1 |
| Q1 FY2019 | Mar 31, 2019 | 60.4% | +2.9 |
| Q4 FY2018 | Dec 31, 2018 | 72.5% | +8.4 |
| Q3 FY2018 | Sep 30, 2018 | 63.8% | +14.2 |
| Q2 FY2018 | Jun 30, 2018 | 59.4% | +4.6 |
| Q1 FY2018 | Mar 31, 2018 | 57.5% | +33.4 |
| Q4 FY2017 | Dec 31, 2017 | 64.1% | +0.0 |
| Q3 FY2017 | Sep 30, 2017 | 49.6% | – |
| Q2 FY2017 | Jun 30, 2017 | 54.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 24.1% | – |
| Q4 FY2016 | Dec 31, 2016 | 64.1% | – |
See a number that looks wrong?